Garching n. Muenchen, Germany, (May 16, 2018) – OncoBeta GmbH has announced today that the Italian Ministry of Health has issued the registration for the Rhenium-SCT® (Skin Cancer Therapy) as a class II b medical device. Following the registration in Germany, Italy is the next country in the EU to register this new painless treatment for non-melanoma skin cancer. Due to the great benefits of the Rhenium-SCT®, it has been currently offered in Celano, Italy and at the University of Bologna, Italy under special authorization.
“This opens new possibilities in Italy for the painless and personalized treatment of Basal Cell and Squamous Cell Carcinomas.” says Shannon Brown the CEO and Managing Director of OncoBeta GmbH “It is now possible for the Rhenium-SCT® to be offered to patients everywhere in Italy. The next centers are lined up preparing to start.”
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the EU.
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.
Find out more about the Rhenium-SCT® at www.oncobeta.com